Deciphera Pharmaceuticals, Inc. (DCPH): Price and Financial Metrics
GET POWR RATINGS... FREE!
DCPH POWR Grades
- Value is the dimension where DCPH ranks best; there it ranks ahead of 71.51% of US stocks.
- DCPH's strongest trending metric is Quality; it's been moving up over the last 179 days.
- DCPH ranks lowest in Stability; there it ranks in the 4th percentile.
DCPH Stock Summary
- For DCPH, its debt to operating expenses ratio is greater than that reported by merely 12.83% of US equities we're observing.
- Revenue growth over the past 12 months for Deciphera Pharmaceuticals Inc comes in at 128.45%, a number that bests 93.43% of the US stocks we're tracking.
- The volatility of Deciphera Pharmaceuticals Inc's share price is greater than that of 98.84% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to Deciphera Pharmaceuticals Inc, a group of peers worth examining would be ADAP, BCDA, MIST, EXEL, and SURF.
- Visit DCPH's SEC page to see the company's official filings. To visit the company's web site, go to www.deciphera.com.
DCPH Valuation Summary
- DCPH's price/sales ratio is 21.9; this is 476.32% higher than that of the median Healthcare stock.
- DCPH's price/sales ratio has moved NA NA over the prior 48 months.
- DCPH's price/sales ratio has moved NA NA over the prior 48 months.
Below are key valuation metrics over time for DCPH.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| DCPH | 2021-08-31 | 21.9 | 4.1 | -7.1 | -6.8 |
| DCPH | 2021-08-30 | 21.7 | 4.1 | -7.0 | -6.8 |
| DCPH | 2021-08-27 | 21.2 | 4.0 | -6.9 | -6.6 |
| DCPH | 2021-08-26 | 20.5 | 3.8 | -6.6 | -6.4 |
| DCPH | 2021-08-25 | 20.6 | 3.9 | -6.7 | -6.4 |
| DCPH | 2021-08-24 | 19.7 | 3.7 | -6.4 | -6.1 |
DCPH's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- DCPH has a Quality Grade of D, ranking ahead of 19.93% of graded US stocks.
- DCPH's asset turnover comes in at 0.137 -- ranking 232nd of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows DCPH's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.137 | 0.980 | -0.586 |
| 2021-03-31 | 0.104 | 0.993 | -0.553 |
| 2020-12-31 | 0.062 | 0.995 | -0.544 |
| 2020-09-30 | 0.033 | 0.996 | -0.556 |
| 2020-06-30 | 0.011 | 0.999 | -0.565 |
| 2020-03-31 | 0.044 | 1.000 | -0.565 |
DCPH Price Target
For more insight on analysts targets of DCPH, see our DCPH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $68.50 | Average Broker Recommendation | 1.36 (Strong Buy) |
DCPH Stock Price Chart Interactive Chart >
DCPH Price/Volume Stats
| Current price | $11.84 | 52-week high | $11.87 |
| Prev. close | $11.37 | 52-week low | $6.51 |
| Day low | $11.04 | Volume | 1,067,100 |
| Day high | $11.87 | Avg. volume | 1,398,882 |
| 50-day MA | $9.91 | Dividend yield | N/A |
| 200-day MA | $8.79 | Market Cap | 784.01M |
Deciphera Pharmaceuticals, Inc. (DCPH) Company Bio
Deciphera Pharmaceuticals LLC develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. Its product pipeline includes Altiratinib (DCC-2701), a MET/TIE2/VEGFR2/TRK kinase inhibitor; DCC-2618, a pan-KIT inhibitor; Rebastinib, a TIE2/VEGFR1 kinase inhibitor; and LY3009120 (DP-4978), a pan-RAF inhibitor. The company was founded in 2003 and is based in Waltham, Massachusetts.
Latest DCPH News From Around the Web
Below are the latest news stories about Deciphera Pharmaceuticals Inc that investors may wish to consider to help them evaluate DCPH as an investment opportunity.
Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right NowNo summary available. |
Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steve Hoerter on Q4 2021 Results - Earnings Call TranscriptDeciphera Pharmaceuticals, Inc. (DCPH) Q4 2021 Earnings Conference Call February 08, 2022, 04:30 PM ET Company Participants Maghan Meyers - SVP, Argot Partners Steve Hoerter - President and CEO Dan Martin - Chief Commercial Officer Tucker Kelly - CFO Conference Call Participants Jessica Fye - JPMorgan Eun Yang - Jefferies... |
H.C. Wainwright Thinks Deciphera Pharmaceuticals’ Stock is Going to RecoverIn a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Deciphera Pharmaceuticals (DCPH – Research Report), with a price target of $15.00. The company's shares closed last Tuesday at $8.16, close to its 52-week low of $7.36. According to TipRanks.com, Fein has 0 stars on 0-5 stars ranking scale with an average return of -2.4% and a 36.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Amylyx Pharmaceuticals, Inc., and Global Blood Therapeutics. Deciphera Pharmaceuticals has an analyst consensus of Hold, with a price target consensus of $13.75. |
Deciphera (DCPH) Q4 Loss Wider Than Expected, Revenues BeatDeciphera (DCPH) reports wider-than-expected loss in the fourth quarter while revenues beat estimates. Stock down is after-hours trading. |
Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial ResultsWALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the fourth quarter and year ended December 31, 2021, and provided a corporate update. “I am immensely proud of our organization’s achievements in 2021 and believe that we are well positioned for long-term success as we work towards our expected milestones in 2022,” said Steve Hoerter, President and Chief Executive Officer of Deciphera Pharmaceuticals. “While the unexpected result |
DCPH Price Returns
| 1-mo | 15.29% |
| 3-mo | 47.82% |
| 6-mo | 36.72% |
| 1-year | 43.38% |
| 3-year | 95.30% |
| 5-year | N/A |
| YTD | 21.19% |
| 2021 | -31.52% |
| 2020 | -8.31% |
| 2019 | 196.52% |
| 2018 | -7.41% |
| 2017 | N/A |
Continue Researching DCPH
Want to see what other sources are saying about Deciphera Pharmaceuticals Inc's financials and stock price? Try the links below:Deciphera Pharmaceuticals Inc (DCPH) Stock Price | Nasdaq
Deciphera Pharmaceuticals Inc (DCPH) Stock Quote, History and News - Yahoo Finance
Deciphera Pharmaceuticals Inc (DCPH) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...